Ajinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all.
Ajinomoto Bio-Pharma today announced it is buying the 50% share of the joint venture still owned by Indian partner Granules OmniChem (GOC). The JV was first established in 2011 and operates a plant in Visakhapatnam that manufactures small-molecule intermediates and active pharmaceutical ingredients (APIs). Terms of the deal were not disclosed.
RELATED: Ajinomoto Bio-Pharma Services takes control of GeneDesign
“GOC has been a well-run producer of high-quality API since its formation, which was designed, constructed and is managed based on our Belgian sites’ GMP operating standards and quality systems,” Ajinomoto Bio-Pharma CEO David Enloe said in a statement.
This move follows several others as the company expands and consolidates its operations. In 2018, then Ajinomoto Althea and U.S.-based OmniChem combined their large- and small-molecule operations. Ajinomoto Bio-Pharma Services, which is a wholly owned subsidiary of Tokyo-based Ajinomoto, earlier this year folded GeneDesign into its operations.
RELATED: Catalent expands Kentucky solid dose plant even as it moves into gene therapy
The CDMO in 2016 acquired the Japanese CDMO that produces nucleic acid drugs but kept it as a separate company. The operation has a 2,000-square-meter facility in Osaka that manufactures oligonucleotide APIs and does custom synthesis.
The moves by the company mirror some of the steps taken by other CDMOs to expand operations in a variety of areas. Somerset, New Jersey-based Catalent, for one, this year laid out $1.2 billion for Paragon Bioservices to bust into the gene therapy realm. It then followed that up with a $40 million investment at its manufacturing facility in Winchester, Kentucky, to boost its formulation and controlled-release tablet and capsule manufacturing.
Ajinomoto Bio-Pharma Services 正在全面控制印度的一家原料药制造工厂，因为 CDMO 继续在一个有利于能够做到这一切的公司的市场中扩张。味之素生物医药公司 (Ajinomoto Bio-Pharma) 今日宣布，将收购印度合作伙伴 OmniChem (GOC) 仍拥有的合资企业 50% 的股份。合资公司成立于 2011 年，在 Visakhapatnam 经营一家工厂，生产小分子中间体和活性药物成分 (API)。交易条款未披露。相关：Ajinomoto Bio-Pharma Services 掌握了 GeneDesign 免费每日通讯这样的故事？订阅 FiercePharma！生物制药是一个快速增长的世界，每天都有大的想法出现。我们的订户依靠 FiercePharma 作为最新的新闻、分析和数据的必读来源，以及制药公司。今天注册，以获得医药新闻和更新交付到您的收件箱和阅读的走。Ajinomoto Bio-Pharma 首席执行官 David Enloe 在一份声明中表示，现在订阅“GOC 自成立以来一直是一家运营良好的高质量 API 生产商，该公司的设计、建造和管理均基于我们比利时工厂的 GMP 操作标准和质量体系。”随着公司的扩张和业务的巩固，此举紧随其后。2018 年，Ajinomoto Althea 和美国的 OmniChem 将其大分子和小分子业务合并。总部位于东京的 Ajinomoto 的全资子公司 Ajinomoto Bio-Pharma Services 今年早些时候将 GeneDesign 折入运营。相关：Catalent 在进军基因治疗领域的同时，也扩张了肯塔基固体剂量工厂——2016 年，CDMO 收购了生产核酸药物的日本 CDMO，但将其作为一家独立的公司保留下来。该行动在大阪有一个 2000 平米的工厂，生产寡核苷酸原料药，并做定制合成。该公司的举措反映了其他 CDMO 为在多个领域扩大业务而采取的一些步骤。萨默塞特，总部位于新泽西的 Catalent 公司，今年为 Paragon Bioservices 公司布局 12 亿美元，进军基因治疗领域。随后，该公司在肯塔基州温彻斯特市的生产工厂投资 4000 万美元，以促进其制剂和控释片剂及胶囊的生产。
扫码实时看更多精彩文章
微博
微信
提交成功！